Skip to content
Roboearth – Lifestyle
Author:
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
May 26, 2026
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
May 21, 2026
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
May 14, 2026
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
May 13, 2026
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
May 12, 2026
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
May 5, 2026
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
April 22, 2026
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
April 14, 2026
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
April 7, 2026
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
March 26, 2026
1
2
Next Page
→